Levofloxacin

Antibioticprescriptionoral · inferred

Broad-spectrum respiratory fluoroquinolone active against gram-negative, atypical, and some gram-positive (including S. pneumoniae) pathogens. Near-complete oral bioavailability (~99%) allows IV-to-PO transition without dose change. Typical 500-750 mg once daily. FDA black-box warnings for tendinopathy/rupture, peripheral neuropathy, CNS effects, and exacerbation of myasthenia gravis.

Projected serum levels — 500 mg, once daily

Levofloxacin
Levofloxacin modeled serum levels, 500 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 125 250 375 500 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 500 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 331 mg, trough ≈ 0.82 mg body load. Population-based estimate over 15 days for a 500 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Antibiotic
Route modeled
Oral
Model confidence
inferred
Half-life
6.9 h
Common dose
500 mg
Suggested maximum
750 mg/day
Reference dose range
250–750 mg (single dose)
Suggested cadence
once daily
Validated against
500 mg oral — Cmax 5.7 mg/L at 1.3 h

Documented interactions

  • warning
    Diltiazem + Levofloxacin QTc prolongation

    Diltiazem and Levofloxacin both prolong cardiac repolarisation (l type calcium channel and herg). Combined risk of QTc prolongation and torsades de pointes.

  • warning
    Felodipine (Plendil) + Levofloxacin QTc prolongation

    Felodipine (Plendil) and Levofloxacin both prolong cardiac repolarisation (l type calcium channel and herg). Combined risk of QTc prolongation and torsades de pointes.

  • warning
    Kava (Kavalactones) + Levofloxacin QTc prolongation

    Kava (Kavalactones) and Levofloxacin both prolong cardiac repolarisation (l type calcium channel and herg). Combined risk of QTc prolongation and torsades de pointes.

  • warning
    Nifedipine (Procardia / Adalat) + Levofloxacin QTc prolongation

    Levofloxacin and Nifedipine (Procardia / Adalat) both prolong cardiac repolarisation (l type calcium channel and herg). Combined risk of QTc prolongation and torsades de pointes.

  • warning
    Oxcarbazepine (Trileptal) + Levofloxacin QTc prolongation

    Levofloxacin and Oxcarbazepine (Trileptal) both prolong cardiac repolarisation (l type calcium channel and herg). Combined risk of QTc prolongation and torsades de pointes.

  • caution
    Azithromycin (Z-Pack / Zithromax) + Levofloxacin QTc prolongation

    Azithromycin (Z-Pack / Zithromax) and Levofloxacin both prolong cardiac repolarisation (herg). Combined risk of QTc prolongation and torsades de pointes.

Serum checks 41 modeled interaction pairings for levofloxacin across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. The pharmacokinetics of levofloxacin in healthy volunteers and patients Fish DN, Chow AT · Clinical Pharmacokinetics, 1997 DOI

    Foundational PK review establishing levofloxacin's 99% oral bioavailability, 6-8 hour half-life, predominantly renal elimination, and linear kinetics supporting once-daily dosing up to 750 mg.

  2. Fluoroquinolones and the risk for ruptures of the Achilles tendon in elderly patients van der Linden PD et al. · Archives of Internal Medicine, 2003 DOI

    Population case-control study of 1841 Achilles tendon ruptures showing fluoroquinolone exposure conferred a 3-fold increased risk, particularly in elderly and corticosteroid users, evidence underlying the FDA black-box…

  3. A Double-Blind, Randomized Comparison of Levofloxacin 750 mg Once-Daily for Five Days with Ciprofloxacin 400/500 mg Twice-Daily for 10 Days for the Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis Peterson J et al. · Urology, 2008 DOI

    RCT of 1109 patients with cUTI/pyelonephritis demonstrated levofloxacin 750 mg x 5 days was non-inferior to ciprofloxacin 400/500 mg BID x 10 days, supporting high-dose short-course strategy.

3 published studies referenced in the app, each with a plain-language summary.